These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

599 related items for PubMed ID: 11268266

  • 41. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.
    Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J.
    Circulation; 2001 Dec 18; 104(25):3046-51. PubMed ID: 11748098
    [Abstract] [Full Text] [Related]

  • 42. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
    Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RA, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A, LIPID Study Investigators.
    Circulation; 2002 Mar 12; 105(10):1162-9. PubMed ID: 11889008
    [Abstract] [Full Text] [Related]

  • 43. The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group.
    Rubins HB, Robins SJ, Collins D.
    Am J Cardiol; 1996 Sep 01; 78(5):572-5. PubMed ID: 8806347
    [Abstract] [Full Text] [Related]

  • 44. Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study.
    Zema MJ.
    J Am Coll Cardiol; 2000 Mar 01; 35(3):640-6. PubMed ID: 10716466
    [Abstract] [Full Text] [Related]

  • 45. Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus. NIDDM Study Group.
    Sweany AE, Shapiro DR, Tate AC, Goldberg RB, Stein EA.
    Clin Ther; 1995 Mar 01; 17(2):186-203. PubMed ID: 7614520
    [Abstract] [Full Text] [Related]

  • 46. Helsinki Heart Study. New perspectives in the prevention of coronary heart disease.
    Huttunen JK, Frick MH, Heinonen OP, Heinsalmi P, Manninen V, Mänttäri M, Romo M.
    Drugs; 1988 Mar 01; 36 Suppl 3():32-6. PubMed ID: 3076118
    [Abstract] [Full Text] [Related]

  • 47. Low high-density lipoprotein cholesterol and other coronary heart disease risk factors in patients with total cholesterol levels greater than 5.17 mmol/L (200 mg/dL) in family practice. A report from CEN.
    J Am Board Fam Pract; 1991 Mar 01; 4(5):285-97. PubMed ID: 1746296
    [Abstract] [Full Text] [Related]

  • 48. Optimal therapy of low levels of high density lipoprotein-cholesterol.
    Kashyap ML, Tavintharan S, Kamanna VS.
    Am J Cardiovasc Drugs; 2003 Mar 01; 3(1):53-65. PubMed ID: 14727946
    [Abstract] [Full Text] [Related]

  • 49. Influence of risk factors on peripheral and cerebrovascular disease in men with coronary artery disease, low high-density lipoprotein cholesterol levels, and desirable low-density lipoprotein cholesterol levels. HIT Investigators. Department of Veterans Affairs HDL Intervention Trial.
    Papademetriou V, Narayan P, Rubins H, Collins D, Robins S.
    Am Heart J; 1998 Oct 01; 136(4 Pt 1):734-40. PubMed ID: 9778079
    [Abstract] [Full Text] [Related]

  • 50. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.
    Koskinen P, Mänttäri M, Manninen V, Huttunen JK, Heinonen OP, Frick MH.
    Diabetes Care; 1992 Jul 01; 15(7):820-5. PubMed ID: 1516498
    [Abstract] [Full Text] [Related]

  • 51. HDL in atherosclerosis: actor or bystander?
    Asztalos BF, Schaefer EJ.
    Atheroscler Suppl; 2003 Mar 01; 4(1):21-9. PubMed ID: 12714034
    [Abstract] [Full Text] [Related]

  • 52. Changes in lipid measures and incident coronary heart disease: Tehran Lipid & Glucose Study.
    Nejat A, Mirbolouk M, Mohebi R, Hasheminia M, Tohidi M, Saadat N, Azizi F, Hadaegh F.
    Clin Biochem; 2014 Sep 01; 47(13-14):1239-44. PubMed ID: 24657509
    [Abstract] [Full Text] [Related]

  • 53. Distribution of lipid phenotypes in community-living men with coronary heart disease. High prevalence of isolated low levels of high-density lipoprotein cholesterol.
    Rubins HB, Schectman G, Wilt TJ, Iwane MK.
    Arch Intern Med; 1992 Dec 01; 152(12):2412-6. PubMed ID: 1456850
    [Abstract] [Full Text] [Related]

  • 54. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct 01; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 55. Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized, double-blind, placebo-controlled, crossover study.
    Miller M, Bachorik PS, McCrindle BW, Kwiterovich PO.
    Am J Med; 1993 Jan 01; 94(1):7-12. PubMed ID: 8420303
    [Abstract] [Full Text] [Related]

  • 56. Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: further insights from the Veterans Affairs High-Density Lipoprotein Intervention Trial.
    Miller M.
    Am J Cardiol; 2000 Dec 21; 86(12A):23L-27L. PubMed ID: 11374852
    [Abstract] [Full Text] [Related]

  • 57. Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial.
    Adabag AS, Mithani S, Al Aloul B, Collins D, Bertog S, Bloomfield HE, Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
    Am Heart J; 2009 May 21; 157(5):913-8. PubMed ID: 19376321
    [Abstract] [Full Text] [Related]

  • 58. The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients. For the Gemfibrozil Study Group.
    Avogaro A, Piliego T, Catapano A, Miola M, Tiengo A.
    Acta Diabetol; 1999 Jun 21; 36(1-2):27-33. PubMed ID: 10436249
    [Abstract] [Full Text] [Related]

  • 59. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I, Benderly M, Sidi R, Boyko V, Tenenbaum A, Tanne D, Behar S.
    Am J Cardiol; 2009 Jan 01; 103(1):41-5. PubMed ID: 19101227
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.